Glial S100B is elevated in serum across the spectrum of west nile virus infection

Muscle and Nerve

Volumn 45, Issue 6, 2012, Pages 826-830

  Leis, A Arturo ^a   Stokic, Dobrivoje S ^a   Petzold, Axel ^b,c  

^a METHODIST REHABILITATION CENTER   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glial S100B; Protein biomarkers; Serum; West Nile fever; West Nile virus

Indexed keywords

PROTEIN S100B;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEUROGLIA; S100 PROTEINS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84860893509     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23241     Document Type: Article

References (38)

1. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137: 173-179.
2. Gyure KA. West Nile virus infections. J Neuropathol Exp Neurol 2009; 68: 1053-1060.
3. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344: 1807-1814.
4. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 2006; 57: 181-194.
5. Leis AA, Stokic DS. Neuromuscular manifestations of human West Nile virus infection. Curr Treat Options Neurol 2005; 7: 15-22.
6. Centers for Disease Control and Prevention (CDC). West Nile virus infection: clinical description.
7. Klee AL, Maidin B, Edwin B, Poshni I, Mostashari F, Fine A, et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004; 10: 1405-1411.
8. Leis AA, Stokic DS, Webb RM, Slavinski SA, Fratkin J. Clinical spectrum of muscle weakness in human West Nile virus infection. Muscle Nerve 2003; 28: 302-308.
9. Sejvar JJ, Leis AA, Stokic DS, Campbell GL, Pape J, Biggerstaff BJ, et al. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis 2003; 9: 788-793.
10. Centers for Disease Control and Prevention (CDC). Acute flaccid paralysis syndrome associated with West Nile virus infection-Mississippi and Louisiana, July-August 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 825-828.
11. Davis LE, DeBiasi R, Goade DE, Halland KY, Harrington JA, Harnar JB, et al. West Nile virus neuroinvasive disease. Ann Neurol 2006; 60: 286-300.
12. Leis AA, Fratkin J, Stokic DS, Harrington T, Webb RM, Slavinski SA. West Nile polymyelitis. Lancet Infect Dis 2003; 3: 9-10.
13. Fratkin JD, Leis AA, Stokic DS, Slavinski SA, Geiss RW. Spinal cord neuropathology in human West Nile virus infection. Arch Pathol Lab Med 2004; 128: 533-537.
14. Kelley TW, Prayson RA, Isada CM. Spinal cord disease in West Nile virus infection. N Engl J Med 2003; 348: 564-566.
15. Kelley TW, Prayson RA, Ruiz AI, Isada CM, Gordon SM. The neuropathology of West Nile virus meningoencephalitis. A report of two cases and review of the literature. Am J Clin Pathol 2003; 119: 749-753.
16. Jeha LE, Hanes GP, Sila CA, Lederman RJ, Isada CM, Gordon SM. Long-term outcome of patients with West Nile virus infection. Infect Dis Clin Pract 2005; 13: 101-103.
17. Sejvar JJ, Haddad MB, Tierney BC, Campbell GL, Marfin AA, van Gerpen JA, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290: 511-515.
18. Petzold A, Groves M, Leis AA, Scaravilli F, Stokic DS. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve 2010; 41: 42-49.
19. Petzold A, Keir G, Lim D, Smith M, Thompson EJ. CSF and serum S100B: release and wash-out pattern. Brain Res Bull 2003; 61: 281-285.
20. Petzold A, Green AJE, Keir G, Fairley S, Kitchen N, Smith M, et al. Serum S100B in brain injury: an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med 2002; 30: 2705-2710.
21. Unden J, Romner B. Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis. J Head Trauma Rehabil 2010; 25: 228-240.
22. Kleindienst A, Bullock MR. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 23: 1185-1200.
23. Townend WJ, Guy MJ, Pani MA, Martin B, Yates DW. Head injury outcome prediction in the emergency department: a role for protein S100B. J Neurol Neurosurg Psychiatry 2002; 73: 542-546.
24. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 2007; 6: 121-138.
25. Unden J, Christensson B, Bellner J, Alling C, Romner B. Serum S100B levels in patients with cerebral and extracerebral infectious disease. Scand J Infect Dis 2004; 36: 10-13.
26. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 2004; 56: 1229-1234.
27. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Janigro D. Extracranial sources of S100B do not affect serum levels. PLoS One 2010; 5: e12691.
28. Waterloo K, Ingebrigtsen T, Romner B. Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury. Acta Neurochir 1997; 139: 26-32.
29. Ingebrigtsen T, Waterloo K, Jacobsen EA, Langbakk B, Romner B. Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery 1999; 45: 468-476.
30. Ingebrigtsen T, Romner B, Marup-Jensen S, Dons M, Lunqvist C, Bellner J, et al. The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Injury 2000; 14: 1047-1055.
31. Lamers KJ, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull 2003; 61: 261-264.
32. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999; 30: 1190-1195.
33. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000; 31: 2670-2677.
34. Kleine TO, Benes L, Zöfel P. Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull 2003; 61: 265-279.
35. Giovannoni G. CSF GFAP. Volcanic ash from anti-aquaporin-4 antibody-mediated destruction of astrocytes [editorial]. Neurology 2010; 75: 200-201.
36. Watson JT, Pertel PE, Jones RC, Siston AM, Paul WS, Austin CC, et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med 2004; 141: 360-365.
37. Sejvar JJ, Curns AT, Welburg L, Jones JF, Lundgren AM, Capuron L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol 2008; 2: 477-499.
38. Berner YN, Lang R, Chowers MY. Outcome of West Nile fever in older adults. J Am Geriatr Soc 2002; 50: 1844-1846.